Page URL: https://www.bionews.org.uk/page_93863

'Holy grail' results two years on in small cardiac stem cell heart failure trial

12 November 2012
Appeared in BioNews 681

Eight heart attack patients given injections of stem cells harvested from their own hearts all show improvement in their heart function two years after treatment. The patients, who were enlisted in an early clinical trial, received only one injection of the cells and no adverse effects were reported.

The results were announced at an American Heart Association conference. An accompanying statement from the university hospitals involved in the study proclaimed that 'for a phase I clinical trial, these results are the holy grail'.

Lead author of the trial, Professor Roberto Bolli, of the University of Louisville, USA, called the results 'exciting; the effect of these cells has continued for up to two years, and has gotten stronger. There was also a major reduction in heart scarring'.

In the study, cardiac stem cells were taken from patients who had suffered heart attacks and were undergoing heart bypass surgery. These cells were kept in vitro and encouraged to proliferate before being injected in large numbers into the damaged heart tissue of the original patients.

Four months after treatment patients' hearts were pumping seven percent more blood with every beat than before. Eight of these patients also had a longer follow-up and two years after the injection, an average increase of 12.9 percent was observed. No improvement was noted for the 13 control patients from whom stem cells were extracted but did not receive the injections.

The treatment also considerably reduced scar tissue. Nine patients had heart scans and new heart tissue had replaced the tissue destroyed by the heart attack in every case.

The researchers say the scan for one patient showed no evidence of his previous two heart attacks. 'What is striking is that we are seeing what appears to be a long-lasting improvement in function', commented Professor Piero Anversa of Brigham and Women's Hospital, Boston, USA, who co-presented the study with Professor Bolli.

The trial will be continued for a further two years to expand upon the current results and Professor Bolli says the findings also 'warrant larger, phase II studies. If [these] continue to confirm our findings, we potentially have a cure for heart failure because we will have something that conceivably, for the first time, actually regenerates dead heart tissue'.

The use of cardiac stem cells to treat heart failure patients is a relatively novel approach. Use of bone marrow-derived stem cells is slightly better established but a study presented at the conference using this approach was less encouraging. The trial, led Dr Jay Traverse from the Minneapolis Heart Institute Foundation in the USA, found no evidence that, six months after an intervention, heart function had improved in patients who had had bone marrow stem cell treatment after a heart attack.

Dr Traverse said that the trial nonetheless demonstrated that 'stem cell therapy is safe, and [had] set a baseline in terms of quantity of stem cells, type of stem cells, and severity of heart attack'.

SOURCES & REFERENCES
Cardiac stem cells may help treat heart failure
American Heart Association (press release) |  6 November 2012
Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial Up to 2 Years After Therapy
American Heart Association |  6 November 2012
SCIPIO: Cardiac stem cells reverse heart failure
theheart.org |  6 November 2012
Stem cells vs. heart attacks
CNN Health |  6 November 2012
Studies On Stem Cell Therapy After Heart Attack Show Mixed Results
RedOrbit |  7 November 2012
Two years out, all patients receiving autologous stem cell therapy show sustained improvement in heart function
University of Louisville (press release) |  6 November 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
18 March 2019 - by Caroline Casey 
The Lancet has retracted a 2011 paper reporting clinical trial data using cardiac stem cells isolated by Dr Piero Anversa's former laboratory...
17 October 2016 - by Dr Jane Currie 
Researchers in Japan have used stem cells from a matched donor to repair damaged heart muscle in macaque monkeys...
12 May 2014 - by Dr Greg Ball 
Two major reviews of clinical trials using stem cells to treat advanced heart disease have found a positive effect of the stem cell treatment, but caution against overstating this effect until more trials are carried out...
7 May 2013 - by Siobhan Chan 
Gene therapy will be used to treat heart failure for the first time in the UK, in clinical trials being launched by the British Heart Foundation...
7 January 2013 - by Dr Greg Ball 
Immune cells that can recognise and kill cancer cells have been grown from induced pluripotent stem cells (iPSCs)...
11 June 2012 - by Dr Rebecca Hill 
A previously unidentified type of stem cell, usually dormant in blood vessels, is at the heart of vascular disease, according to researchers...
15 May 2012 - by Helen Brooks 
Stem cell therapy may benefit patients with chronic heart disease, according to the results of a small clinical trial carried out by US scientists....
5 March 2012 - by Cathy Holding 
A major clinical trial to investigate a stem cell treatment for chronic ischemic heart disease (IHD) – a leading cause of death around the world – has begun in the US...
20 February 2012 - by Cathy Holding 
A stem cell-based therapy aiming to reverse the damage caused by heart attacks has shown positive results in an early clinical trial...
21 November 2011 - by Victoria Kay 
The world's first clinical trial using patients' own cardiac stem cells to repair heart damage has produced surprising results. The preliminary trial was designed simply to test the safety of the procedure, but doctors observed an unexpected improvement in heart function in patients receiving the treatment...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.